Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
Launched by IMPERIAL COLLEGE LONDON · Sep 29, 2005
Trial Information
Current as of July 28, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying hereditary hemorrhagic telangiectasia (HHT), a condition that affects blood vessels and can cause bleeding. The researchers aim to understand the specific genes involved in this condition by examining DNA samples from families who have been affected by HHT. This could help improve our understanding of the disease and potentially lead to better treatments in the future.
To participate, you need to be a member of a family that has been diagnosed with HHT. The trial is open to people of all ages and genders. If you decide to join, you will provide a DNA sample, which is a simple process. It’s important that you are comfortable with this and can give your permission to participate. This study is currently recruiting participants, and your involvement could contribute valuable information to help others with HHT.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Member of family affected by HHT
- Exclusion Criteria:
- • Unable or unwilling to provide informed consent for DNA sample
About Imperial College London
Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Claire L Shovlin
Principal Investigator
Imperial College London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials